Beam, Apellis partner in deal to expand gene editing's reach

Bio Pharma Dive

The companies aim to develop therapies for complement-driven diseases, a specialty of Apellis and relatively new research ground for gene editing

Gene editing biotech Verve to raise $267M in large IPO

Bio Pharma Dive

Capitalizing on investor interest in gene editing, the high-profile startup has secured one of the richest biotech initial public offerings priced this year

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Intellia, with first results, delivers a 'landmark' for CRISPR gene editing

Bio Pharma Dive

Results published in The New England Journal of Medicine offer the first clinical evidence that CRISPR gene editing inside the body can be safe and effective, a culmination of years of scientific research

Caribou raises $304M in one of gene editing's most lucrative IPOs

Bio Pharma Dive

The IPO is several times larger than what CRISPR Therapeutics, Intellia and Editas raised several years ago, and ranks well ahead of a more recent offering from gene editing startup Beam

Lilly dives into gene editing

Bio Pharma Dive

Through a deal with Precision Biosciences, the pharma aims to develop therapies for genetic disorders, including Duchenne muscular dystrophy

Gene editing: beyond the hype

Pharma Phorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Zinc fingers are the most common control gene in the body,” Macrae explains. “We Gene therapy can ultimately only take you into the liver,” he explains.

After long wait, Editas reveals first data for CRISPR gene editing treatment

Bio Pharma Dive

Early study results offer some hopeful signs of efficacy, but the small number of patients treated and short follow-up limit firmer conclusions

Prime Medicine raises $315M to fuel 'search-and-replace' gene editing work

Bio Pharma Dive

Formed around research from the Broad Institute's David Liu and Andrew Anzalone, Prime has attracted significant funding from a wide range of high-profile biotech backers

Vertex, looking to broaden its gene editing abilities, asks a young biotech for help

Bio Pharma Dive

A freshly inked agreement gives Vertex the right to use tools from Arbor Biotechnology to develop "ex vivo" cell therapies for diseases like Type 1 diabetes and sickle cell, among others

JPM21: Gene editing for heart disease, a new date to watch in Alzheimer's and Pfizer's deep pockets

Bio Pharma Dive

Verve, a buzzy gene editing startup, unveiled its first drug candidate on Tuesday, while Eli Lilly's and Pfizer's CEO gave updates on Alzheimer's and dealmaking

GenEdit Uncloaks to Solve Gene Editing “Delivery Problem”

BioSpace

Kunwoo Lee has uncloaked his solution to the gene-editing “delivery problem” with $26 million in Series A funds for his company, GenEdit

CRISPR, with new partner, to develop gene editing therapies for ALS, nerve disorder

Bio Pharma Dive

A deal with biotech startup Capsida, which recently raised $140 million, gives CRISPR access to a Caltech technology that aims to improve the delivery of genetic medicines

Gene Editing Breakthroughs Accelerate Heart, Stroke Research

BioSpace

?Gene therapy research delivers breakthroughs this week with a CRISPR-edited droplet that could lead to a cure for heart disease and the possibility of turning glial brain cells into neurons

A CRISPR gene editing treatment continues to show promise for two blood diseases

Bio Pharma Dive

Results from 10 patients with beta thalassemia or sickle cell disease show CRISPR Therapeutics and Vertex's pioneering treatment to be effective, building on earlier study data

Editas, AbbVie rework gene editing deal as pioneering CRISPR trial resumes

Bio Pharma Dive

Development of EDIT-101, the first CRISPR-based therapy to be used in a company-led trial to alter genes within a person's body, will now move forward under Editas' sole ownership

Medicine of the Future Happening Today - Seelos Sees Promise for In Vivo Gene Editing

BioSpace

This appears to be a second example of CRISPR gene editing inside the body, as opposed to in cell cultures

Doudna-founded biotech Caribou raises fresh funds to fuel gene editing pipeline

Bio Pharma Dive

The CRISPR biotech raised $115 million in a Series C financing aimed at advancing its engineered cell therapy research

#news #biotech UK clears the way for gene-edited crops

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: UK clears the way for gene-edited crops. from European Biotechnology – first and foremost in European biotech [link].

Will Intellia Make Gene Editing History Saturday?

BioSpace

In what will be a big moment for CRISPR technology, Intellia and development partner, Regeneron Pharmaceuticals will share the world’s first data from a therapy that edits flawed genes inside the body

Vertex builds in gene editing yet again, with $1.2bn Arbor deal

Pharma Phorum

Vertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of months, agreeing a partnership with CRISPR specialist Arbor Biotechnologies that could be worth up to $1.2

ERS Genomics Licenses CRISPR Gene Editing Technology to Otsuka Pharmaceutical

BioTech 365

A Pivotal Moment for CRISPR in the Gene Editing Journey

BioSpace

With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space

#news #biotech UK permits development of gene-edited crops in climate fight

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: UK permits development of gene-edited crops in climate fight.Britain’s government plans to allow researchers to use gene-editing techniques to develop crops that can increase yields, reduce the … Continue reading → #news

Beam, Verve stockpile cash as investors bank on gene editing progress

Bio Pharma Dive

Beam expects to receive $260 million through a private stock placement, while Verve raised $94 million to support initial studies of its heart disease treatment

Gene-editing produces tenfold increase in superbug slaying antibiotics

Scienmag

Martins Scientists have used gene-editing advances to achieve a tenfold increase in the production of super-bug targeting formicamycin antibiotics. Credit: Dr Dino J.

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021

BioTech 365

Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021 DURHAM, N.C.–(BUSINESS –(BUSINESS WIRE)–Precision BioSciences, Inc. Nasdaq: DTIL), a clinical stage biotechnology company … Continue reading → Business Wire

Researchers recommend more transparency for gene-edited crops

Scienmag

Media contacts: Jennifer Kuzma, jkuzma@ncsu.edu Khara Grieger, kdgriege@ncsu.edu Mick Kulikowski, News Services, 919.218.5937 or mick_kulikowski@ncsu.edu Researchers at North Carolina State University call for a coalition of biotech industry, government and non-government organizations, trade organizations, and academic experts to work together to provide basic information about gene-edited crops to lift the veil on how plants or […].

#news #biotech Researchers invent new gene-editing tool

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Researchers invent new gene-editing tool.Researchers from the University of Illinois Chicago have discovered a new gene-editing technique that allows for the programming of sequential cuts—or edits—over time.

CRISPR touts new results as fresh questions surround 'off-the-shelf' CAR-T

Bio Pharma Dive

The gene editing company aims to expand its trial and add a second dose to improve effectiveness. However, safety worries have emerged since the FDA ordered CRISPR's rival Allogene to suspend clinical work

Merit-based NSF grant extension supports expansion of gene-editing technology

Scienmag

Credit: Rasgon Lab, Penn State Researchers who developed an improved method of gene editing for the study of arthropods will expand the technology for use in vertebrate species such as mice, fish and birds after receiving new funding from the National Science Foundation.

$80 Million-Plus Venture Rounds for Gene Editing, Fusion Protein Companies

BioSpace

Sizable venture rounds from cardiac gene-editing company Verve Therapeutics and the retooled fusion protein maker Vera Therapeutics will push their lead therapies into and through the clinic over the next two years

Paper: Congress must clarify limits of gene-editing technologies

Scienmag

–Genome editing of human embryos represents one of the most contentious potential scientific applications today. But what if geneticists could sidestep the controversy by editing sperm and eggs instead? Credit: Photo by L. Brian Stauffer CHAMPAIGN, Ill.

#news #biotech WHO details steps to ensure human gene editing is safe, ethical

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: WHO details steps to ensure human gene editing is safe, ethical.The World Health Organization published a slew of recommendations Monday on how to ensure gene editing research … Continue reading → #news

Japanese consumers more concerned about gene-editing of livestock than of vegetables, survey shows

Scienmag

Credit: Photo by Hisashi Urashima A statistically rigorous survey of Japanese consumers has found that they have more negative opinions about the use of new gene-editing techniques on livestock than they do about use of the same technologies on vegetables.

QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments

BioTech 365

QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments QIAGEN Launches Dedicated CRISPR Products for Rapid and Simplified Analysis of Gene-Editing Experiments QIAprep&amp CRISPR Kit and Q-Primer Solutions expand QIAGEN portfolio for CRISPR applications Products are … Continue reading → Business Wire

Advancing gene editing with new CRISPR/Cas9 variant

Scienmag

Those two key problems – safety and efficacy – are what continue to hold CRISPR-Cas9 gene targeting back from its full clinical potential, explains co-senior author Y. Using a new variant to repair DNA will improve both safety and effectiveness of the much-touted CRISPR-Cas9 tool in genetic research, Michigan Medicine researchers say.

Gene-edited babies: Current techniques not safe, say experts

The Pharma Data

Current scientific techniques are not yet safe or effective enough to be used to create gene-edited babies, an international committee says. The world’s first gene-edited babies were born in China in November 2018. Why is gene-editing babies controversial?

8 key clinical trials to watch for the rest of 2021

Bio Pharma Dive

The next six months could feature clinical milestones for CRISPR gene editing, the treatment of COVID-19, microbiome drugs and gene-targeted cancer therapy

#news #biotech Gene editing could render mosquitos infertile, reducing disease spread

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Gene editing could render mosquitos infertile, reducing disease spread.Mosquitos spread viruses that cause potentially deadly diseases such as Zika, dengue fever and yellow fever.

Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal

BioTech 365

Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal The new agreement will provide Lonza with access to Arbor’s gene editing technology Quote from David Cheng, CEO … Continue reading → GlobeNewswire

#news #biotech Prime editing enables precise gene editing without collateral damage

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Prime editing enables precise gene editing without collateral damage.The latest gene editing technology, prime editing, expands the ‘genetic toolbox’ for more precisely creating disease models and correcting … Continue reading → #news

Verve Therapeutics Announces Data Demonstrating Durable LDL Cholesterol Lowering After a One-Time Gene Editing Treatment in Non-Human Primates

BioTech 365

#news #biotech Advancing gene editing with new CRISPR/Cas9 variant

BioTech 365

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Advancing gene editing with new CRISPR/Cas9 variant.Using a new variant to repair DNA will improve both safety and effectiveness of the much-touted CRISPR-Cas9 tool in genetic research, … Continue reading → #news